Drug Trial Radar · NCT00768300
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Last checked: Nov 20, 2026Latest source record: Apr 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
494
Actual
Start
Dec 2008
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Oct 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
AmbrisentanDrug
Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
PlaceboDrug
Placebo to match ambrisentan was administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Death or Disease (IPF) Progression.Time frame: Up to 48 months
Locations
185 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Hospital
Birmingham, Alabama
Pulmonary Associates
Phoenix, Arizona
Site not named
Scottsdale, Arizona
David Geffen School of Medicine at UCLA(Harbor-UCLA Medical Center)
Los Angeles, California
University of California, Davis
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Stanford University
Stanford, California
National Jewish Medical And Research Center
Denver, Colorado
Site not named
Newark, Delaware
Bay Area Chest Physicians
Clearwater, Florida
University of Miami Miller School of Medicine
Miami, Florida
Site not named
Tampa, Florida
Emory University
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Site not named
Council Bluffs, Iowa
Kentuckiana Pulmonary Association
Louisville, Kentucky
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Saint Lukes Foundation
Chesterfield, Missouri
Dartmouth Medical School
Lebanon, New Hampshire
Site not named
New Brunswick, New Jersey
Site not named
Piscataway, New Jersey
Pulmonary & Allergy Associates
Summit, New Jersey
Pulmonary And Critical Care Services, P.C.
Albany, New York
Winthrop University Hospital
Mineola, New York
Site not named
New Hyde Park, New York
Site not named
New York, New York
Columbia University Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Site not named
Cincinnati, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Site not named
Columbus, Ohio
The Oregon Clinic, P.C.
Portland, Oregon
University of Pennsylvania Health Systems
Philadelphia, Pennsylvania
Showing 40 of 185 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.